Quote | Lexaria Bioscience Corp. (NASDAQ:LEXX)
Last: | $3.13 |
---|---|
Change Percent: | -1.67% |
Open: | $3.05 |
Close: | $3.13 |
High: | $3.24 |
Low: | $2.93 |
Volume: | 110,863 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
News | Lexaria Bioscience Corp. (NASDAQ:LEXX)
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing warrants. Specifically, the agreement is comprised of the purchase of 2,917,032 shares of commo...
KELOWNA, BC / ACCESSWIRE / April 30, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has entered into a warrant exercise agreement with an existing accredited investor to exercise in full certain...
Message Board Posts | Lexaria Bioscience Corp. (NASDAQ:LEXX)
Subject | By | Source | When |
---|---|---|---|
Dont get too excited down 11% pre market | PotsandPans420 | investorshub | 05/19/2023 12:18:24 PM |
Hope Springs Eternal! | Shawking | investorshub | 05/19/2023 4:33:47 AM |
Be interesting to see if we see any | PotsandPans420 | investorshub | 05/18/2023 8:09:02 PM |
https://www.globenewswire.com/en/news-release/2021/02/23/2180141/28124/en/Global | Shawking | investorshub | 05/18/2023 7:45:25 PM |
Rush of price activity and volume more news coming? | codfather | investorshub | 05/18/2023 6:00:14 PM |
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Company Name:
LEXX Stock Symbol:
NASDAQ Market:
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing warrants. Specifically, the agreement is comprised of the purchase of 2,917,032 shares of commo...
KELOWNA, BC / ACCESSWIRE / April 30, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has entered into a warrant exercise agreement with an existing accredited investor to exercise in full certain...
Lexaria, a global innovator in drug delivery platforms, has received approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board GLP-1 drugs are utilized in the treatment of type 2 diabetes and obesity, a huge market, and are typically administered by painful a...